Fosun Pharma, TPG agree to buy Chindex

Chinese drugmaker Shanghai Fosun Pharmaceutical Group Co Ltd and private equity firm TPG Capital are to buy China-focused Chindex International Inc in a beefed-up $461 million deal after trumping a rival bid, writes Reuters. The U.S.-listed healthcare firm signed a sweetened merger agreement after the consortium raised its offer to $24 per share from its original $19.50 per share, Chindex said in a statement late on Monday.

DealsNorth AmericaUSBriefs